TR201910508T4 - Prostat kanserinin tedavisi ve prostat kanseri hastalarına yönelik prognozun belirlenmesine yönelik bir yöntem. - Google Patents

Prostat kanserinin tedavisi ve prostat kanseri hastalarına yönelik prognozun belirlenmesine yönelik bir yöntem. Download PDF

Info

Publication number
TR201910508T4
TR201910508T4 TR2019/10508T TR201910508T TR201910508T4 TR 201910508 T4 TR201910508 T4 TR 201910508T4 TR 2019/10508 T TR2019/10508 T TR 2019/10508T TR 201910508 T TR201910508 T TR 201910508T TR 201910508 T4 TR201910508 T4 TR 201910508T4
Authority
TR
Turkey
Prior art keywords
prognosis
prostate cancer
determining
question
patient
Prior art date
Application number
TR2019/10508T
Other languages
English (en)
Inventor
Andersson Tommy
Bjartell Anders
Original Assignee
Wntresearch Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wntresearch Ab filed Critical Wntresearch Ab
Publication of TR201910508T4 publication Critical patent/TR201910508T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Mevcut buluş, özel olarak radikal prostatektomi geçirmiş veya geçirecek olan hastalarda, prostat kanserinin tedavisinde kullanım için, bir Wnt5a proteini veya bunun Wnt5a sinyallemesi özelliklerine sahip olan peptidi, örneğin, Foxy5, ile ilgilidir. Buluş ayrıca, prostat kanseri olan bir hasta için bir prognozu belirlemek için bir yöntem ve söz konusu yöntemi gerçekleştirmek için bir kit ile de ilgilidir. Bir hasta için bir prognozu belirlemek için yöntem aşağıdaki adımları içerir: hastadan daha önceden elde edilen bir örneğin en azından parçasında bulunan Wnt5a proteininin bir miktarını değerlendirme ve değerlendirilen miktara karşılık gelen bir örnek değeri belirleme; adım a)'da elde edilen örnek değerini bir referans prognoz ile ilişkilendirilmiş bir referans değer ile karşılaştırma ve söz konusu örnek değeri söz konusu referans değere kıyasla daha yüksek olduğunda, söz konusu hasta için prognozun söz konusu referans prognoza kıyasla daha iyi olduğu sonucunu çıkarma.
TR2019/10508T 2011-07-01 2012-06-28 Prostat kanserinin tedavisi ve prostat kanseri hastalarına yönelik prognozun belirlenmesine yönelik bir yöntem. TR201910508T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1150619 2011-07-01

Publications (1)

Publication Number Publication Date
TR201910508T4 true TR201910508T4 (tr) 2019-08-21

Family

ID=47437285

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10508T TR201910508T4 (tr) 2011-07-01 2012-06-28 Prostat kanserinin tedavisi ve prostat kanseri hastalarına yönelik prognozun belirlenmesine yönelik bir yöntem.

Country Status (8)

Country Link
US (1) US9278119B2 (tr)
EP (1) EP2726880B1 (tr)
DK (1) DK2726880T3 (tr)
ES (1) ES2735540T3 (tr)
HU (1) HUE045368T2 (tr)
PL (1) PL2726880T3 (tr)
TR (1) TR201910508T4 (tr)
WO (1) WO2013006129A1 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6921755B2 (ja) * 2014-12-10 2021-08-18 ハイパーステム ソシエテ アノニム 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
ES2963914T3 (es) * 2017-10-25 2024-04-03 Wntresearch Ab Péptidos de WNT5A en la reducción de células madre cancerosas
WO2020053200A1 (en) * 2018-09-10 2020-03-19 Wntresearch Ab Peptides for use in treatment of psoriasis
WO2020212514A1 (en) * 2019-04-16 2020-10-22 Wntresearch Ab Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601363B1 (fr) 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
WO1998023730A1 (en) 1996-11-27 1998-06-04 The Penn State Research Foundation Compounds and methods for treating cancer
WO2000031261A2 (en) 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor
EP1033405A3 (en) 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
EP1226172A1 (en) 1999-11-05 2002-07-31 Forskarpatent i Syd AB Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
ATE299494T1 (de) 1999-12-07 2005-07-15 Theravance Inc Carbamat-derivate als muscarin-rezeptor antonisten
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
EP1594447A2 (en) 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2543473T3 (es) 2005-05-30 2015-08-19 Wntresearch Ab Un ligando peptídico para alterar la migración de células cancerígenas
WO2009134204A1 (en) 2008-04-30 2009-11-05 Forskarpatent I Syd Ab RESTORATION OF ESTROGEN RECEPTOR-α ACTIVITY
RU2517190C2 (ru) 2008-08-13 2014-05-27 Внтрисерч Аб Применение производных пептида wnt5-a для лечения меланомы и рака желудка
WO2012109540A1 (en) 2011-02-10 2012-08-16 Fox Chase Cancer Center Methods for inducing epithelial cancer cell senescence

Also Published As

Publication number Publication date
US20140206623A1 (en) 2014-07-24
HUE045368T2 (hu) 2019-12-30
EP2726880A1 (en) 2014-05-07
DK2726880T3 (da) 2019-07-15
US9278119B2 (en) 2016-03-08
WO2013006129A1 (en) 2013-01-10
EP2726880B1 (en) 2019-04-17
PL2726880T3 (pl) 2019-09-30
EP2726880A4 (en) 2015-03-04
ES2735540T3 (es) 2019-12-19

Similar Documents

Publication Publication Date Title
BR112016011025A8 (pt) anticorpo humanizado anti calicreina-2.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
BR112012008665A2 (pt) tratamento de câncer
NZ595340A (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
MX2018003077A (es) Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica.
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
EA201391587A1 (ru) Комбинированная терапия на основе hsp90
UA113712C2 (xx) Антитіло до fap і способи його застосування
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
WO2011073215A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
TR201910508T4 (tr) Prostat kanserinin tedavisi ve prostat kanseri hastalarına yönelik prognozun belirlenmesine yönelik bir yöntem.
MX2015000686A (es) Metodo para detectar cancer.
WO2012079878A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MY179845A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
RU2016141144A (ru) Способ супрессии злокачественной опухоли посредством ингибирования тмсс3